SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

Atlantis Healthcare Report Reveals New Hepatitis C Treatment Will Require Patient-Centric Adherence Support

CRANFORD, N.J., April 8, 2014 /PRNewswire/ -- The arrival of new oral drugs for treatment of hepatitis C will dramatically shift the landscape of therapy from being physician-driven to patient-led, raising questions about best practices for adherence.  A White Paper published by Atlantis Healthcare offers a roadmap of the new therapeutic environment for pharma industry, healthcare providers and organized customers, including clinical insights, non-adherence predictors and proven interventions to improve adherence.

Established in 1993, Atlantis Healthcare creates and executes tailored patient support programs and personalized interventions to address treatment adherence across a wide range of chronic and acute diseases, worldwide. Led by one of the world's largest health psychology teams, our patient-centric approach is designed to improve health outcomes and deliver optimal value for all healthcare stakeholders

"Adherence is critical and we need to be on top of that," said Professor David Goldberg, leader of Health Protection Scotland's hepatitis C program and contributor to the latest report from the Adherence Research Summarized series. "The new drugs are expensive and there is the possibility that the virus could become resistant if adherence is sub-optimal, so we will need to support people to take the medication."

Hepatitis C is a virus carried in the blood affecting 170 million people worldwide. In the US, more than 3.2 million people live with chronic hepatitis C, with 16,000 new cases diagnosed each year.  According to the report, while therapy offers the possibility of cure, the majority of people living with hepatitis C do not receive treatment. For those who do start treatment, good outcomes are dependent on a high level of adherence.

Current treatment for hepatitis C involves weekly interferon injections combined with oral drugs.  Side effects, include fatigue, headache and depression, are the most common reason for discontinuing treatment. The new drugs are in simple pill form, bypassing the need for injections or frequent hospital visits, and offer shorter duration of treatment and improved effectiveness.  

"With the new therapies coming on line, much of the demand for the treatment will come from the patients," said Dr. Goldberg.  "They will hear it's much easier to take, more effective, has fewer side effects and can be taken without disrupting one's work."

According to the report, the greater patient responsibility in hepatitis C therapy will present challenges to the healthcare community, especially when supporting hepatitis C patients who have other chronic conditions.  Research reviewed indicates that simple patient-led interventions, including personalized nursing support and supplemental patient education from a health care provider other than the physician, can help increase treatment adherence.

For more information and to download the report, visit http://atlantishealthcare.com/hepatitis-c-white-paper/

Logo - http://photos.prnewswire.com/prnh/20130627/MM38791

SOURCE Atlantis Healthcare

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.